for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ImmunoGen, Inc.

IMGN.OQ

Latest Trade

2.68USD

Change

0.27(+10.97%)

Volume

508,594

Today's Range

2.39

 - 

2.70

52 Week Range

1.76

 - 

7.26

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Immunogen Inc Says Will Not Incur A Loss On Estimated Sub-Lease Arrangement Disclosed On June 27

Aug 5 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN INC -$2.5 MILLION CHARGE WILL BE INCLUDED IN RESULTS FOR PERIOD ENDED JUNE 30 IN CONNECTION WITH DISPOSITION OF SPACE AND EQUIPMENT.IMMUNOGEN INC - WILL NOT INCUR A LOSS ON ESTIMATED SUB-LEASE ARRANGEMENT DISCLOSED ON JUNE 27.

Immunogen Reports Q2 Loss Per Share $0.29

Aug 2 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN REPORTS RECENT PROGRESS AND SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.29.Q2 REVENUE $15.5 MILLION VERSUS $9.3 MILLION.Q2 REVENUE ESTIMATE $9.5 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES DATA.UPDATED 2019 FINANCIAL GUIDANCE PROVIDED.SEES FY 2019 REVENUES BETWEEN $40 MILLION AND $45 MILLION.REGISTRATION STUDY FOR MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER ON TRACK TO START BY YEAR-END.FY2019 REVENUE VIEW $36.1 MILLION -- REFINITIV IBES DATA.

Immunogen Says Savings Generated By Restructuring Are Expected To Reduce Co's Quarterly Expenses By More Than 50%

June 27 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN ANNOUNCES COMPLETION OF OPERATIONAL REVIEW.IMMUNOGEN INC SAYS WILL END CURRENT QUARTER WITH ABOUT $240 MILLION ON ITS BALANCE SHEET.IMMUNOGEN INC SAYS WILL PRIORITIZE CONTINUED DEVELOPMENT OF MIRVETUXIMAB SORAVTANSINE AND A SELECT PORTFOLIO OF EARLIER-STAGE CANDIDATES.IMMUNOGEN INC SAYS MONETIZE ITS REMAINING PORTFOLIO AND PLATFORM TECHNOLOGIES THROUGH OUT-LICENSING TRANSACTIONS OR ASSET SALES.IMMUNOGEN INC SAYS REDUCE WORKFORCE BY ABOUT 220 EMPLOYEES, WITH MAJORITY OF EMPLOYEES SEPARATING FROM BUSINESS BY MID-JULY 2019.IMMUNOGEN INC SAYS SAVINGS GENERATED BY RESTRUCTURING ARE EXPECTED TO REDUCE IMMUNOGEN'S QUARTERLY EXPENSES BY MORE THAN 50%.IMMUNOGEN INC SAYS AS RESULT OF WORKFORCE REDUCTION, EXPECTS TO RECORD A ONE-TIME CHARGE TOTALING ABOUT $16.4 MILLION.IMMUNOGEN INC SAYS CHARGE EXPECTED TO BE RECORDED IN QUARTER ENDING JUNE 30, AND RELATED CASH PAYMENTS WILL BE SUBSTANTIALLY PAID OUT BY JUNE 30, 2020.IMMUNOGEN INC SAYS CASH RUNWAY EXTENDED THROUGH READOUT OF MIRVETUXIMAB SORAVTANSINE PIVOTAL TRIAL IN OVARIAN CANCER.IMMUNOGEN - OPERATIONAL REVIEW COMMENCED FOLLOWING ANNOUNCEMENT THAT FORWARD I, CO'S PHASE 3 CLINICAL TRIAL EVALUATING MIRVETUXIMAB DID NOT MEET PRIMARY ENDPOINT.

Immunogen Evaluates Next Steps With Mirvetuximab Monotherapy In Platinum-Resistant Ovarian Cancer Patients

May 15 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN - EVALUATING POTENTIAL NEXT STEPS WITH MIRVETUXIMAB MONOTHERAPY IN PLATINUM-RESISTANT OVARIAN CANCER PATIENTS WITH HIGH FR EXPRESSION LEVELS.IMMUNOGEN INC - GENERATED ENCOURAGING DATA WITH MIRVETUXIMAB COMBINATION REGIMENS.IMMUNOGEN INC - WILL EVALUATE ONGOING STUDIES AS AN INDEPENDENT PATH FORWARD TO SUPPORT A REGISTRATION IN OVARIAN CANCER..

ImmunoGen says FDA Has Recommended Co Conduct A New Phase 3 Randomized Trial To Evaluate Safety And Efficacy Of Mirvetuximab Soravtansine

May 15 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN PROVIDES REGULATORY UPDATE ON MIRVETUXIMAB SORAVTANSINE MONOTHERAPY IN OVARIAN CANCER.IMMUNOGEN INC - FORWARD I DID NOT MEET ITS PRIMARY ENDPOINT UNDER PRE-SPECIFIED STATISTICAL ANALYSIS PLAN.IMMUNOGEN INC - FDA HAS RECOMMENDED THAT COMPANY CONDUCT A NEW PHASE 3 RANDOMIZED TRIAL TO EVALUATE SAFETY AND EFFICACY OF MIRVETUXIMAB SORAVTANSINE.IMMUNOGEN INC - FDA PROVIDED GUIDANCE REGARDING DESIGN AND ENDPOINTS OF A POTENTIAL REGISTRATION STUDY.

Immunogen Reports Q1 Loss Per Share Of $0.30

May 3 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.30.Q1 REVENUE $8.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $10.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.20 -- REFINITIV IBES DATA.HAD $270.4 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2019, COMPARED WITH $262.3 MILLION AS OF DECEMBER 31, 2018.ENCOURAGING EFFICACY SIGNAL OBSERVED IN PRE-SPECIFIED SUBSET OF PATIENTS IN PHASE 3 FORWARD I STUDY.TO MEET WITH REGULATORS THIS QUARTER TO DISCUSS POTENTIAL PATH FORWARD FOR MIRVETUXIMAB SORAVTANSINE MONOTHERAPY.OPERATIONAL REVIEW UNDERWAY WITH GOAL OF EXTENDING CASH POSITION.WILL PROVIDE AN UPDATE ON 2019 FINANCIAL GUIDANCE FOLLOWING COMPLETION OF OPERATIONAL REVIEW.

Immunogen Announces Top-Line Results From Phase 3 Forward I Study Of Mirvetuximab Soravtansine In Ovarian Cancer

March 1 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 FORWARD I STUDY OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER.IMMUNOGEN INC - TRIAL DID NOT MEET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL.IMMUNOGEN INC - EFFICACY SIGNAL SEEN IN HIGH FOLATE RECEPTOR ALPHA PATIENTS; ADDITIONAL ANALYSES TO BE CONDUCTED.IMMUNOGEN INC - FAVORABLE TOLERABILITY PROFILE CONFIRMED.IMMUNOGEN INC - COMBINATION REGIMENS TO BE EVALUATED AS AN INDEPENDENT PATH FORWARD TO SUPPORT REGISTRATION IN OVARIAN CANCER.IMMUNOGEN INC - EFFICACY SIGNAL SEEN IN HIGH FOLATE RECEPTOR ALPHA PATIENTS.IMMUNOGEN INC - WILL FURTHER ASSESS DATA FROM FORWARD I TO DETERMINE POTENTIAL NEXT STEPS WITH A MONOTHERAPY APPROACH.IMMUNOGEN INC - MIRVETUXIMAB SORAVTANSINE WAS WELL-TOLERATED IN STUDY.

Immunogen Reports 2018 Operating Results

Feb 8 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN REPORTS RECENT PROGRESS AND 2018 OPERATING RESULTS.SEES FY 2019 REVENUE $40 MILLION TO $45 MILLION.HAD $262.3 MILLION IN CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2018.SEES CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2019 TO BE BETWEEN $135 MILLION AND $140 MILLION.SEES 2019 OPERATING EXPENSES BETWEEN $265 AND $270 MILLION.QTRLY LOSS PER SHARE $0.28.QTRLY TOTAL REVENUES $13.8 MILLION VERSUS $39.4 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.32, REVENUE VIEW $12.3 MILLION -- REFINITIV IBES DATA.

Immunogen Inc - Expects To Report That As Of Dec 31, 2018 It Had Cash And Cash Equivalents Of About $262.3 Million

Jan 8 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN INC - EXPECTS TO REPORT THAT AS OF DEC 31, 2018 IT HAD CASH AND CASH EQUIVALENTS OF ABOUT $262.3 MILLION.

Immunogen Announces Sale Of Residual Kadcyla Royalties

ImmunoGen Inc <IMGN.O>::IMMUNOGEN ANNOUNCES SALE OF RESIDUAL KADCYLA ROYALTIES.IMMUNOGEN INC - COMPANY TO RECEIVE $65 MILLION PAYMENT.IMMUNOGEN INC - OMERS NOW OWNS 100% OF IMMUNOGEN'S RIGHTS TO RECEIVE KADCYLA ROYALTIES.IMMUNOGEN INC - TRANSACTION ENTAILS SALE OF RESIDUAL INTEREST HELD BY CO FROM A PRIOR TRANSACTION WITH IMMUNITY ROYALTY HOLDINGS, L.P..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up